An Evaluation of the Effect of Community-based Pharmacist Intervention on Patients With Chronic Pain

Chronic Pain Clinical Trial

Official title:

An Evaluation of the Effect of Community-based Pharmacist Intervention on Patients With Chronic Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03087331
• Other study ID #: 21092
• Status: Completed
• Phase: N/A
• First received: May 10, 2016
• Last updated: November 15, 2017
• Start date: February 2016
• Est. completion date: May 2017

Study information

• Verified date: November 2017
• Source: University of Waterloo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, pre post, pilot cohort study to be conducted in patients with chronic pain, which is defined as pain that lasts beyond 3 months. To accomplish the primary and secondary objectives of the study, three phrases will be designed and completed during three months

Description:

This study will evaluate the effectiveness of community-based pharmacist interventions on the quality of life of patients with chronic pain as determined by self-reported pain levels using an established scoring system. Participating pharmacists will enroll chronic pain patients from their normal practice to receive a consultation, which consists of an assessment of their current pain, a medication review, and education about their condition. Based on the information provided by the patient, the pharmacist will prepare a care plan, contact the patient's prescriber, and, in conjunction with the prescriber, implement the plan to help relieve their pain. Follow-up assessments will be done after 2 weeks, and 3 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Aged 18 or older

2. Baseline average pain intensity using Brief Pain Inventory is 6 or higher

3. Ambulatory and able to attend the intervention

4. Complaining of pain for 3 months or longer

Exclusion Criteria:

1. Patients with malignant or cancer pain

2. Patients who are unable to communicate in English

3. Non-ambulatory and unable to attend the intervention at the participating site

4. Unable to give informed consent.

Related Conditions & MeSH terms

• Chronic Pain

Intervention

Other:
• medication reviews, assessment, recommendations, education.

Locations

Country	Name	City	State
Canada	The PharmaShoppe	Kitchener	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University of Waterloo

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	patient adherence	Patient adherence will be measured using Morisky medication adherence scale-8, and will be measured at 2 weeks and 3 months follow-up.The Morisky medication adherence scale-8 will be used as supplementary data to further elucidate potential factors behind the observed outcomes.	2 weeks follow-up and 3 months follow-up
Primary	Pain intensity change	Pain intensity will be measured with Brief Pain Inventory pain intensity subscale, and will be measured 3 times in total	baseline, 2 weeks follow-up, 3 months follow-up
Secondary	Pain interference	Pain interference will be measured with Brief Pain Inventory pain interference subscale, and will be measured 3 times in total	baseline, 2 weeks follow-up, 3 months follow-up
Secondary	Quality of life change	quality of life will be measured using Short Form-36, and will be measured twice in total.	baseline, 3 months follow-up